francine: this is the man in charge of europe's most valuable company, novo nordisk, and its blockbuster diabetes and obesity drugs ozempic and wegovy. both contain the key ingredient semaglutide, revolutionizing the weight loss market and generating billions in sales. celebrities have helped their popularity soar. sharon osbourne, chelsea handler, and elon musk have all publicly talked about taking ozempic or wegovy, and they've had further backing from oprah winfrey. it's a global phenomenon, reaching millions on social media apps, including tiktok. but it's not without controversy, including possible side effects, high prices, and the company's lobbying efforts receiving criticism around the world. and in some cases, patients might also need to take the drugs indefinitely to avoid regaining the weight. chief executive lars fruergaard jorgensen says obesity is a disease and thinks the company will learn from its growing number of patients. lars: when i ask the scientists, they say the priority and mechanism will tell you that it's chronic treatment. my personal view is that we will als

[city noise] noesk novo nordisk do you charge forward? freeze in your tracks? (♪♪) or, let curiosity light the way. at t. rowe price, we're asking smart questions about opportunities like clean water. and how clean water advances can help transform our tomorrows. better questions. better outcomes. t. rowe price pete g. writes, "my tween wants a new phone. how do i not break the bank?" we got you, pete. xfinity mobile was designed to save you money and gives you access to wifi speeds up to a gig. so you get high speeds for low prices. better than getting low speeds for high prices. right, bruce? -jealous? yeah, look at that. -honestly. someone get a helmet on this guy. xfinity internet customers, get a free unlimited line for a year when you buy one unlimited line. >>> welcome back to fast money, jpmorgan, goldman sachs, some of the marquee banks beating earnings estimates. bny, discover, financial and american express hitting new highs today. everything about this environment is great for financials, karen. >> it really is. i mean, on every front. you have net

francine: this is the man of -- in charge of novo nordisk and its blockbuster diabetes and obesity drugs, ozempic and wego v. both contain the key ingredient semi-glue tide, revolutionizing the weight loss market and generating billions in sales. celebrities have helped their popularity soared. sharon osbourne, chelsea handler and elon musk have all talked about publicly taking ozempic or wego v. it's a global phenomenon reaching millions on social media apps, including tiktok. but it's not without controversy including possible side effects, high prices on the company's lobbying for seen criticism around the world. in some cases patients might need to take the drugs indefinitely to avoid regaining the weight. the chief executive says obesity is a disease and think the company will learn from its growing number of patients. >> my personal view is that we will also feel that taste -- patients are -- much different and will be different. so there will have to be a portfolio of inventions. francine: i travel to the firm's headquarters in copenhagen, denmark. i asked lars about the global se

novo nordisk posted a really strong early trial results for one of its experimental drugs that showed patients can lose more weight versus previous drugs. keep in mind, stocks -- the stock is down by 14% over the past 12 months. it's a long way to recover. scarlet: good stuff. natalia kinazhevich thank you for the numbers. we are still waiting for the first trade from a venture global. that stock, when it does begin trading is under the ticker vg. another currency market all strength has been a theme since the election of donald trump with the bloomberg dollar index of more than 7% fourth quarter alone. earlier today jay polaski of tbw spoke about the currency's importance. jay: the dollar is key for us. if the dollar rolls over it is bullish on the exposure for 20 25. american exceptionalism at risk. there is no room for mistakes and in the u.s.. that is the main take away. there is room in the rest of the world. so, that audibled anova suggests to us -- the dollar rolling over suggests to us, where are there opportunities elsewhere? scarlet: morgan stanley has a note out focusing on

ultimately, the big expansion and gain for novo nordisk was back in the day when they actually announced first progress with glp-1 drugs. is this now being capped? >> the concern is lily will take share. the glp-1 was disappointing. eli lilly was up 5%. the concern around not concern with obesity market. it is novo nordisk will lose share to eli lilly and their drug is not as good as zepbound is the marketing name. i disagree with that. i think generally speaking, it will still remain a duopoly. one in eight american adults is on glp-1 drugs. we expect that to continue. with that view to continue the glp-1 market is healthy and still a duopoly. the idea of losing share to eli lilly is overton. the valuation is low with the huge penetration growth story in america in particular and health insurance in europe will start covering this as well. super exciting. >> i guess they are trying to see if there are any other areas to advance via the glp-1 drugs. thank you for your time. the head of equities at fulcrum asset management. >>> meanwhile, russian gas ex-ex- s to europe via ukraine have st

we're cheering or investors have cheered novo nordisk for precisely that., has your view changed? i mean, there is still room. i mean, this is feasibly this comes or will come just in time as semaglutide comes off patent. >> yes. >> i think it comes off patent. >> i think there's room if you are there and they are certainly there. so the fact that they are improving on their existing portfolio, i think is important. if it were a newcomer and we saw 22% versus 20, but it it was kind of it needed to be supported by billions of investment that wasn't already, you. >> know, lined. >> up, lined up. i think it's very difficult. and that's why i think if you're amgen, if you're merck and astrazeneca, whomever, very difficult to say that you're going to be a real player. you could generate revenue, but you may not make any money. >> that's what i think difficult today based on this data than yesterday. >> well, certainly, i mean, this data looked like it could be close to best in class. but as every day goes forward here, i think it's more difficult if you're not a

we continue to own that stock. >> what about novo nordisk? this was interesting.nk this is not going away. if you look at the secular drivers behind obesity and the need for these drugs, it's not going away. more importantly, i do think while they may take a short-term revenue hit in terms of lowering price, i think they could gain a significant amount of market share. also, despite the huge obese population, there is an equally large population that does not want to become obese and there is a massive movement towards micro dosing. so i actually think this can still be a relevant drug in that world. >> thank you, appreciate it. >> before we go we'll call it an rbi, random but interesting. i know it's going to be super cold in d.c. for the inauguration. look at hotel prices. we looked on booking.com for sunday to tuesday. it's like $1,000 a night for a hotel that normally would be like $120 a night. we just talked about cars and sufficient costs. suv costs. well hotels for the inauguration in d.c. what else can i old man yell about this week? >> it's a sign of int

we are particularly seeing novo nordisk under pressure within the healthcare space.et's see what will happen there as well. now, one of the main focus for the investors no doubt is the upcoming eurozone. we had the french coming in at 1.8% on the year in december. that is slightly higher than the 1.7% recorded in november. we have at the moment euro tracking higher against the u.s. dollar. we are up .40%. this continuing the moves we had witnessed already on monday, but all in all, i would like to dig deeper and understand the dynamics. charlotte, the figures are coming at a time when the new government trying to decide on fiscal policy. any clarity there? >> we will see. there could be some positive news for the month on december. it is a slight uptick on november. 1.8% against plus 1.7% in november. it was still very much below that ecb target of 2%. that is a different picture from other countries like germany or spain. some positive news. this is a bit of caution for the ecb for the next step. a slight rebound in energy prices and slight uptick in december which

because there we are seeing strong gains for novo nordisk as well an important story to monitor also ahead of earnings next month. in terms of the worst performing sectors. how those are trading at this stage? we have pressure on telecoms down almost half a percent and food and beverage also lower by about 0.2%. i want to show you how u.s. futures are shaping up too so we get a better idea of what's likely to happen. hate suggest a positive start to the trading day on wall street. we had the three major indices ending the day on positive ground. however today's session worth keeping an eye on are the earnings season and of course that's still very much underway. and on top of that of course what's happening at the white house. we continue to monitor everything that donald trump is telling us at this stage. i want to bring you back to europe and tell you about some of the corporate stories we are also following closely today. starting with easy jet. the company narrowed its operating loss in the first quarter amidst stronger demand for travel over the festive period. the budget carrie

novo nordisk, look at this stock, you guys.eporting positive results from the new obesity drug. early stage trials showing weight loss of up to to 22 president matches the number of zepbound which is made by rival eli lilly. >>> intuitive surgical slipping in spite of its upbeat fourth quarter report, issuing lackluster gross margin guidance for 2025. still, citigroup raising its price target from 640 up to 711. deutsche bank upping theirs from about 505 to 585. and one of the big stories of the day, meta's ceo, mark zuckerberg, saying his platform wills invest as much as $65 billion this yearal to expand the a.i. infrastructure. the investment will include building a 2-gigawatt data center and ramping up hiring for a.i. positions. the social networking company also announcing that it will begin limited early testing on its threads app with a handful of brands in the u.s. and japan. and we also just want to say that $65 billion blew away analyst expectations for, like, $50 billion in cap-x, so the spending continues. >>> all ri

novo nordisk seeing steep losses. the stock erasing all its gains back to august of 2023.z joins us on the "fast line." jared, great to have you with us. >> thanks so much for having me, melissa. >> at this point, investors have digested what's going on in novo nordisk in terms of the disappointment with the new drug, and that market share hasn't gone to the rest of the space. what's going on here in terms of the re-evaluation in the multiples here and what's factored into the stock? >> i think the main issue is that we finally are in some sort of air pocket with respect to catalysts for novo. they introduced a couple of datasets in oral over the past -- oral obesity medications over the past six months, and then, this drug, which i thought was actually okay, just didn't look as good as the company had indicated to investors. and i think the underlying problem with, when you look at the entire obesity space, is that the analyst community, i just believe got overzealous with, you know, their out-year estimates, $100 billion, $120 billion. it just became -- for both of the s

minnesota que dependen de la insulina, ahora podrÁn comprarla por 35 $ al mes gracias a un acuerdo con novo nordisko cuerpo produce tanta mucosidad? borja: Éste es un tema de salud no sÓlo para nosotros, sino para toda la familia. hoy queremos conversar con la doctora juanita mora, portavoz de la asociaciÓn americana del pulmÓn, para que nos ayude a entender un poquito mÁs sobre este proceso. y algo importante que pocas veces se habla, el papel que juega la mucosidad en nuestro sistema inmunolÓgico. doctora mara, gracias por acompaÑarnos una vez mÁs aquÍ en la "ediciÓn digital". ¿por quÉ nuestro cuerpo produce mucosidad, y quÉ nos dice eso sobre el funciona mente de nuestro sistema inmunolÓgico? >> buenos dÍas. siempre un gusto . la mucosidad se produce mucho en respuesta que el sistema inmunolÓgico hace cuando entran cosas alÉrgicas, como el polen, el polvo, tambiÉn en respuesta cuando nos enfermamos, un virus que quiere entrar en nuestro cuerpo, una bacteria con los cambios de temperatura extrema, como el frÍo, el calor, ante esta sustancia gelatinosa para atrapar lo que es ese polen no ese polvo

it is unclear whether trump will respect or honor the list but novo nordisk is scheduled to report earningsmonth. for now, shares lower by 5%. sonali: thank you, isabel lee. homebuilders have been moving in the session. today we got u.s. housing data showing new construction in december climbing at the fastest pace since early 2024. all of them ripping quite a bit. we will talk real estate with bess friedman. stick with us for that conversation next. this is bloomberg. ♪ sonali: new u.s. economic data today showing housing starts in the u.s. climbed in december to the fastest pace since early 2024. for more on the real estate market as rates stay high, we are joined by bess freedman, a leading luxury real estate company. rates above 7%. you were talking about how they needed to be below five to unlock the market. it looks like people can't wait. bess: there is volatility right now. it feels very frothy, the environment. it will take time before rates start to come down. people assume that when the fed cut the last time before the end of the year that we would start to see mortgage rates com

david: there's another company in sort of the same business, novo nordisk. they have a similar product. they have a product that does the same thing. one is for obese tirk anti-obesity, one is for diabetes. is there really in difference in terms of the drugs? dave: there are. there's no real difference between the one for die beesby tees and anti-obesity, that's for insurance purposes. right now, because you just ate lunch your g.i. tract is communicating with the rest of the body, communicating with hormones and protein, saying you've been fed uric need to absorb knew trepts and other things that are see en-- essential to life. what we're doing is boosting some of those signals with these medications. they're boosting the signal that you're full. boosting the signal that you no longer want to eat more. boosting signals that you should absorb nutrients you have consumed. our does that with two different hor moans. one, glp-1 and another g.i.p. osemp i think -- ozempic or semaglutide does similar. david: so it affects the way you feel? >> as people eat more h

all the averages are up about 2% for the week though novo nordisk shares are jumping. the trial for a new weight loss drug showed success 22% body weight loss in an early trial covering 125 people. those shares are up 8%, though they're still down 16% on the year. and quantum is back in the news. rigetti is the most actively traded stock on the new york stock exchange today. it's up 3% today, 40% this week, almost 14 a share and flattish on the year after a big drop from those jensen wong comments when he questioned when quantum brian would actually arrive. >> well, the four pizzas we had for lunch as a show, not in that novo nordisk study. all right, kelly, thank you. we've got a lot more to do this hour, but let's start here with some news in retail. as one of america's biggest retailers just decided to back away from some dei initiatives. cnbc retail reporter melissa repko is here with more on that melissa. >> so target said today that it's backing away from some major dei programs, including pledges it made after the police involved. >> murder of. >> george floyd a

david: there's another company in sort of the same business, novo nordisk. which is in denmark. they have a similar product. they have a product that does the same thing. one is for obesity -- anti-obesity and one is for diabetes. is there really in difference in terms of the drugs? dave: there are. there's no difference between the drugs nature diabetes and obesity for either company. that's for insurance reasons. tirzepatide is one of them. it has two modes of action. right now, because you just ate lunch your g.i. tract is communicating with the rest of your body. it is communicating with hormones and protein, saying you have been fed and need to absorb nutrients and other things that are essential to life because food is essential to life. what we're doing is boosting some of those signals with these medications. they're boosting the signal that you're full. boosting the signal that you no longer want to eat more. boosting signals that you should absorb nutrients you have consumed. ours does that with two different hormones. one called glp-1 and another called g.i.p. ozempic

francine: this is the man in charge of europe's most valuable company, novo nordisk, and its blockbusters and obesity drugs ozempic and wegovy.

so keep an eye on novo nordisk up big and another one moving in the opposite direction. today is a name that we often talk about with semiconductors, but not so much like in the in the nvidia scope of things. but texas instruments is off 7%. it's down about $14. this is on the heels of better than expected earnings and profits revenues. everything is good. but the forecast came into question a little bit. it fell below some analysts expectations. and the reason why much of that is due to automotive end market weakness in places like europe, the us and japan. that's the reason why analog chip companies alongside texas instruments are also lower. and kelly. some traders and investors do look towards companies like texas instruments as a general economic bellwether globally, because those analog chips are used in everything from cars to washing machines to guided missile systems. so keep an eye on txn. i'll send things back over. >> to. >> the doctor. copper indicator. >> i like. >> the way that one's. >> going, dom. >> thanks. >> president trump wants the. >> federal reser

shares of novo nordisk are jumping in the premarket trading. the danish drug maker announcing successful early stage trial results for a new experimental weight loss drug that's administered by subcutaneous injection that actually achieved a 22% weight loss after just 36 weeks. novo nordisk, of course, is the company behind the popular weight loss drug wegovy. and shares of the company up almost 10%. if you're looking at the week up by about 13%. and we're going. mike mentioned that the top half of the company said it expects a $4 billion loss for the. >> fourth quarter, though. >> joins us right now with more on this. and phil, i hadn't realized how long it had been since boeing had actually reported a profit. >> six years. >> this is. >> the sixth straight year. >> or 2024 will be the sixth straight year with an annual loss. in fact, it's. going to be a record annual loss. the previous record was 11.9 billion lost in 2020. we haven't got the final numbers yet. looks like when you add in the 4 billion from the fourth quarter, with the 8 billio

novo nordisk, trading at august 2023 lows. it's lost nearly half of its value since late june. >>> and viking thera sank. that is currently in midstage trials. for more on all of this, angelica peebles joins us. angelica? >> a, mel. that's right. lilly's fourth quarter coming up short of expectations. and that is renewing fears that it might also be slowing. >> because of supply tight accident in the first half of the year, inventory levels rose because of uncertainty. as we become a more predictable supplier, people able to work down their capital. and patients can get the medicine they want. >> lilly's new ceo. what they did there was they took the trends that they were seeing earlier in the ear when supplies were tight. and people started pulling back. they weren't ordering as much as they needed or that they were before because there was more supply available. and also learned that there is more seasonable stock available. saying there were just a few things that were a little bit out of whack in those guidance. and some o

we will have interviews with the ceo of novo nordisk and eli lilly and merck.rldwide exchange." "squawk box " starting right no. have a great day. >>> good morning. breaking news from the middle east. negotiators are nearing a deal on the gaza cease-fire. details straight ahead. >>> china officials are reportedly considering a sale of u.s. tiktok business to elon musk as one possibility if the supreme court, in fact, upholds a ban. >>> and starbucks is reversing its open-door policy. it will soon require a purchase for people to hang out in caves or use the bathroom there. it's tuesday, january 14th, 2025 and "squawk box" begins right now. >>> good morning, everybody. welcome to "squawk box" here on cnbc. we are live from the nasdaq market site in times square. i'm becky quick along with joe kernen and andrew ross sorkin. and so far there are some green arrows this morning. actually, pretty decent advances if you are watching the dow up 150 points. nasdaq is up 150 points. the s&p indicated up by 30. yesterday was an interesting session to watch. we were under

that was interesting given denmark's biggest export to the united states is actually ozempic via novo nordisk. tom: one feels these stories have further to run. kriti gupta with a write-down on what we have been hearing from president trump. u.s. stocks got hammered yesterday, as a selloff in the world's biggest bond market deepened on speculation the federal reserve will not cut interest rates now until july, amid inflation risks. let's dive deeper with bloomberg valerie tytel. the ism services, the jobs data, walk us through to the market reaction and the pushing back then of that next cut from the fed. >> it was all about this yields rise yesterday. hot economic data that took another like higher. it also has been having a global effect. in london, u.k. gilt market shaken by the treasury market. yes we have that hot economic data. we also have trump commenting that interest rates are too high. a little bit of i guess the fed coming under pressure from trump already, getting hints of that in his press conference yesterday.let's put this yields rise in perspective because we are very much th

novo nordisk is up today. what's going on there?0% so they just came out with the latest results from one of the latest trials they have with a new weekly injectable weight loss drug. the results so far are good. the average weight reduction was about 22% in obese and overweight people, patients after 36 weeks. so again, once weekly injectable drug. one of the latest that they are putting out maybe to market. david: all right we had a couple of names report before the bell. i want to start with american express. taylor: revenue for the quarter and year up 9%, earnings per share up 16% for the quarter, year-over-year. more importantly they are guiding revenue growth of 8-10% next year and increasing the quarterly dividend by about 17%. david: the market i guess is selling the news with the market right? taylor: a little bit. this is a stock that and again i spoke with the ceo and what he said is you have a little bit of a pullback from small businesses last year, right? because inflation and interest rates, small businesses have a ha

what can you tell me about novo nordisk and their latest obesity drug trial?'m surprised by the market reaction because a few of the headlines. semaglutide. the active ingredient achieved a 20.7% weight loss in obesity trial so basically achieved that primary endpoint by demonstrating significantly significant weight loss, relative to a placebo, right? so within 72 weeks, a higher dose, people lost about 25% of their weight loss. smaller dose? people lost about 17% of their weight. placebo, obviously you lose 0% of your weight so it met the endpoint but again, you know, a decent trial from what we hear. we'll have to dig into see what analysts say about it. stuart: stock is down 3.9%. palantir investing in a new drone start-up company. i believe the company is called shield a.i. what do we know? taylor: they are trying to raise about $200 million but would give shield a.i. a valuation of about $5 billion. so this is sort of classic tie-up where this aligns perfectly with palantir's idea, right? incorporate a.i. into the defense sector. it's not just palantir.

novo nordisk's stock is not taking this well, shares dropping the a 52-week low of $78.87.a chop of about 5%. other names on the list include pfizer's advanced breasts asthma treatment, trely, and ab i have's it until bowel medication. it did give medicare the power to directly hash out drug prices with manufacturers, but it's unclear whether president-elect trump will change or try to scale back some of the law's provisions. trump has in the past said that he supported a path similar the what the biden administration has just taken. >>> let's look at corvo. remember when i told you intel was second best on the intel? -- on the s&p 500? starboard value revealed it has amassed a half billion dollar stake in the chipmaker. filings show starboard now owns 7.7% of corvo which makes radio frequent is city chips -- frequency chips. corvo's stock has been a laggard over the past year, losing about 29%. and she's barbie tough. in the wake of her wildly successful barbie movie, director greta gerwig has gotten netflix to agree to a first. her next film, narnia, based on the c.s. lew

. >> share s of novo nordisk falling.f prescription drugs that potentially will be subject to medicare price negotiations. the negotiations are part of biden's inflation reduction act which gave medicare the power to directly hash out drug prices with manufacturers. you can see shares of novo down 5%. eli down almost 3%. goldman sachs paying ceo david sullivan $80 million to stay put for at least the next five years. $80 million. the board also plans to raise the ceos pay by 26% up to a whopping $39 million. this according to a new filing. shares of goldman sachs are up 2% on the notion he will be at the helm for the next five years. >> stability at the top, i guess the market is happy to see. thank you very much. we're also tracking shares of salesforce today. seema modi with more on that stock's move. >> reporter: hey, mike. analysts at cowen raising their earnings estimates after conducting an extensive survey on how companies are thinking about artificial intelligence budgets going into 2025. and they found that sales

good maker have rallied 8% so far this year and have grabbed the number one title from denmark's novo nordisk giant behind diabetes and weight loss drugs ozempic and wegovy that has fallen 8% year to date over concerns that the u.s. government will push for lower pricing of those therapies barclay says marvell technology and nvidia are leaders when it comes to picking a.i. chip stocks in 2025 the firm hiked nvidia's price target to $175 a share is at 137 and change right now, marvels $250 a share it's 224 in change, barclay says it expects total addressable market in the a.i. chip space to grow all the way through 2026, the world is watching today's inauguration along with america while the new commander-in-chief steam has been credited for playing a big part in the return of three israeli hostages over the weekend, many of the global issues remain, the ukraine war, the china threat, cybersecurity among them, one of the top tech investors in the nation is here to tell us how she sees trumps future foreign policies impacting defense stocks in the sector in catherine boyles is here on a fox bus

. >> yes, a 6% of us adults are now using just eli lilly makes the mazda's novo nordisk about 5 other companies are going to be introducing them in the future the prices down for things like will go vian zepbound. but at the grocery bill up for the average gop one years down 6%. that's pretty impressive for higher income families. it's down 9%. it's less fast. food, less coffee. shop consumption. it's hurting companies like kraft heinz pepsi, hershey, nestle. campbell's, who also kind of like. sections right? but it's so big. it's kind of interesting. you're starting to see like united airlines say that they would save 8 80 million dollars if every pastor lost 10 pounds, i'm probably gonna get on them in the next 3 months because still got that stubborn 10 to 15 pounds to lose be yeah. >> you 10 pounds a bowling ball. you fine. okay. don't know why. i think that there's nothing between cosmetic and like health reasons shed weight. and i i think. i think you're on. >> my doctor ideal weight would be one 9200 now. but last as high as 2.30, to 40. >> ok, well, then stop buying scout cook

ozempic and wegovy are made by novo nordisk, which is based in denmark and has u.s. headquarters in plainsboro, new jersey. >> providing some comfort to firefighters and law enforcement in southern california, we'll introduce you to two pups whose mission it is to help those impacted in disaster zones. [music] >> plus, president elect trump will take the oath of office on monday and rebecca castor in washington with a look at how the nation's capital is preparing for the inauguration. >> coming up and giving you a look there at the mostly cloudy day over the golden gate bridge. it's a cooler one for most. i'll have a look at the current bounced from one doctor to the next. does it have to be like this? at kaiser permanente, we have a different kind of healthcare... so, how did you like doctor lum? ...where all of us work together for all that is you. elect donald trump. security is top of mind too, but the event is also being moved inside due to the weather. rebecca castor has the latest from washington with an arctic blast on the way. >> feels like temperatures on m

shares of novo nordisk are rallying. >> this as. >> a new obesity drug. it's testing shows. significant weight loss. >> its early. >> trial results. >> though. >> and we're keeping an eye on one. >> of the. >> biggest energy. >> ipos we've seen in a decade. >> venture global. america's second. >> largest lng. >> exporter is set to make. >> its. >> debut right here at. the nyse. >> let's begin. >> with the markets this morning and this s&p record run. jim over. >> the. >> last week and a half best eight session rally since august. >> although not. >> as broad as it was last year. >> no. >> but i. >> do like to see that this is a. >> rally. >> that's not. >> led by apple. it's a rally. >> it's not led. >> by nvidia. >> it's a rally where microsoft seems to be tepid. alphabet kind of here nor there. tesla. you have to reignite. >> it. >> with an. >> adam jonas piece talking about an etf etf. of ai. but you'll see these beautiful. >> one off moves. >> union pacific great quarter versus say csx. or how about the drugs. how about the drugs. i mean last week i was at the j.p. morga

novo nordisk shares are jumping in today.plain why in the markets next. >> hey. >> thinking about retirement. would you like to have retirement income that you can count on for the rest of your life? how about up to 33% more income? call this number to get this free book annuity do's and don'ts for baby boomers. this book is filled with valuable information uncovering little known secrets to help you maximize your income in retirement and its free retirement income. you can count on starts by calling for this free book. as a bonus, we'll also rush this annuity rate report. also, absolutely free annuity national researched numerous products and summarize the rates and benefits of annuities from foremost insurance companies like nassau life and annuity call for both these free books. annuity national retirement income you can count on for the rest of your life. call now for your free books. call 800 211 4470. that's 800 211 4470 800 211 4470. >> people everywhere are losing weight with life. md. >> and i'm keeping it. >> off wi

we have a market flash for you on novo nordisk. see right here shares are surging up just about 9.5% on word of a successful clinical trial for a new glp one drug. again the weight loss drug area taking taking a look at the stock right now, as we just said, up about 9.5% after that successful trial. all right. as we close in on the 6 a.m. hour, a few big stories that we're following this morning looking at shares of texas instruments. they're under pressure after signaling ongoing challenges in its auto and industrials markets, which account for about 70% of revenue. the ceo saying they've they've yet to see a bottom also warning of gross profit margin decreases in the months ahead. shares down nearly 5%. other chip makers also falling in sympathy. texas instruments again down about 5%. analog devices on semiconductor and nxp all down more than 1%. boeing shares pulling back following preliminary q4 results. boeing says it expects to take a $4 billion hit in the final three months of 2024. that includes a $1.1 billion charge relate

novo nordisk. talked about their summer. one of the new gop drugs -- gop drugs -- glp drugs.is overdone. positive inflection point for glp-1s. i can hear myself rallying behind ubs. it's whether you think a wipeout on that day is a sufficient entry point for you now. that is the trajectory for the moment. jonathan: manus cranny, appreciate it. an update on some of the movers this morning. we are down here by .4%. under surveillance, canadian political leaders firing back at present elect donald trump's comments about the u.s. annexing canada. justin trudeau writing, "there is not a snowballs chance in hell candidate would become part of the united states." "candidate will never be the 51st state, period." annmarie: i want to lean into the individual that will likely be the next prime minister of canada. he was talking about in his statement that trudeau did not do a good job of explaining how much canada helps the u.s. when it comes to things like oil and gas, agriculture. this will be an interesting one to watch. i think the republicans love trolling trudeau. i wonder if the

. $300 million for novo nordisk. >> what is really driving it is botox. >> 30.7% of ad minutes acrossvening news on abc, nbc and cbs were related to prescription drug brands. >> i find if you watch nfl ads, you get a very good -- those ads by the way are working versus internet ads. one of the things is disappointing about youtube in the fourth quarter of major football games, they put up zen pictures of things like cakes. i would like to have ruth not watch this show as much as i like, put some budweiser. >> zen ads of cakes? is that the new megan markle show? >> okay. i'm glad you brought that up. you remember i said at the beginning of the show, this is doing well and continue to do well. those are the leaders. because there's nothing new. put up constellation energy versus constellation brands. >> there is nothing new with constellation energy. >> those stocks are overdone. you know you can't throw up a nuclear power plant if you have the site. it doesn't work like that. we know that from southern. the small form nuclear reactor in canada being built, these things just don't come

novo nordisk is in the red. ozempic will be subject to pricing negotiations. and then apple rebounds after its worst day since august 5th. stock is down 11%. as far as the overall market, you have this goldilocks data. i think it was supercharged yesterday by him. he hinted that first half cuts were firmly on the table for him if we continue to see good inflation data like we saw this week. i asked him about march. here is what he said. >> january, we need to see what happens. the chair said we are in no rush to do things point we need to see a little more progress on inflation. this month was good, but we need to make sure we get through the turn of the year and make sure it continues. we will have to wait and see. i don't think mark would completely be ruled out, but anything that disrupts that is likely to push back some. as long as the data comes in on inflation and we continue on that path, i can certainly see rate cuts happening sooner than the markets pricing in point >> i asked for specifics. three or four cuts this year he said would not be out of the

novo nordisk, it comes to glp-1's they have a new drug and it is doing well. it is experimental.the six weeks. if you take the placebo, of course i was joking that i get the placebo, you gain 2% over the same period of time. this is reinvigorating the head-to-head challenge with eli lilly and southbound. it is about doing that mode in glp-1's. never mind the mode in chips. henry, good morning. annmarie: thank you so much. looking ahead to next week the fed's first rate decision of the year is coming on wednesday. kathy bostjancic writing, unwavering consumer resilience reinforces the consensus that the fed will hold off on policy changes in the near term. however, we see the fed resuming rate cuts in the second half of 2025, lowering the fed funds rate a total of 50 basis points this year. kathy joins us now. i could be cute and say this is because donald trump is telling the fed to lower interest rates. tell us what you see that you think the fed is going to be able to resume those rate caps. -- rate cuts. kathy: good morning, annmarie. see strong disinflationary impulse in pric